Park Place Capital’s Vertex Pharmaceuticals VRTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$336K Buy
676
+1
+0.1% +$443 0.05% 186
2026
Q1
$301K Buy
675
+50
+8% +$23.3K 0.06% 152
2025
Q4
$283K Buy
625
+70
+13% +$30.2K 0.06% 156
2025
Q3
$217K Buy
555
+279
+101% +$117K 0.05% 184
2025
Q2
$125K Hold
276
0.03% 248
2025
Q1
$134K Sell
276
-89
-24% -$41.5K 0.04% 222
2024
Q4
$147K Buy
365
+36
+11% +$16.7K 0.04% 234
2024
Q3
$153K Sell
329
-41
-11% -$19.7K 0.04% 237
2024
Q2
$173K Sell
370
-422
-53% -$183K 0.06% 227
2024
Q1
$331K Sell
792
-507
-39% -$214K 0.12% 170
2023
Q4
$529K Buy
1,299
+286
+28% +$106K 0.21% 131
2023
Q3
$352K Sell
1,013
-207
-17% -$72.4K 0.1% 177
2023
Q2
$429K Sell
1,220
-213
-15% -$71.8K 0.12% 158
2023
Q1
$451K Sell
1,433
-666
-32% -$200K 0.13% 156
2022
Q4
$606K Buy
+2,099
New +$640K 0.17% 134

Other funds holding VRTX

Park Place Capital's VRTX Position: Q2 2026 in Review

Park Place Capital increased its Vertex Pharmaceuticals (VRTX) stake by 0.15% in Q2 2026, buying an estimated $443 and bringing the position to 676 shares worth $336K. The position accounts for 0.05% of the portfolio, ranked #186.

Park Place Capital first reported a position in VRTX in Q4 2022 and has held it in 15 quarters since. The position peaked at $606K in Q4 2022. 1,757 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Park Place Capital held 676 shares of Vertex Pharmaceuticals worth $336K as of Q2 2026.
  • Park Place Capital bought 1 Vertex Pharmaceuticals share in Q2 2026, an estimated $443.
  • Vertex Pharmaceuticals made up 0.05% of Park Place Capital's portfolio in Q2 2026, its #186 holding.
  • Park Place Capital first reported a position in Vertex Pharmaceuticals in Q4 2022 and has held it in 15 quarters since.
  • Park Place Capital's Vertex Pharmaceuticals position peaked at $606K in Q4 2022.
  • 1,757 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Park Place Capital's 13F filing for Q2 2026, filed 14 Aug 2026.